We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 130 for:    genetics AND Parkinson's disease

Cohorts and Collections: Clinical and Genetic Study of Parkinson's Disease and Epilepsies

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00142363
First Posted: September 2, 2005
Last Update Posted: March 1, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Ministry of Health, France
Information provided by:
Institut National de la Santé Et de la Recherche Médicale, France
  Purpose

The DNA and Cell Bank of Instituts Federatifs de Recherche (IFR) of Neurosciences has been running for the last 15 years at the Institut National de la Santé Et de la Recherche Médicale (INSERM) Unit 679 (former unit 289). Since its creation, this structure has been the support of research projects in genetics for neurological and psychiatric disorders. The cohorts established have led to discoveries in monogenic disorders, such as cerebellar ataxias, spastic paraplegias, frontotemporal dementias, epilepsies, Parkinson’s and Alzheimer’s disease, Charcot-Marie-Tooth disease and related entities. The research projects based on the study of the genetic bases in Parkinson’s disease and epilepsies are especially developed for this grant.

Concerning Parkinson’s disease, the project is based on the extension of the existing cohort throughout the French Parkinson’s Disease Study Group network. Concerning epilepsies, this project is the occasion to build this network with the constitution of a new cohort.

The specific aims of the scientific projects are the following for Parkinson’s disease:

  • to evaluate the frequency, the nature and the phenotype associated with parkin mutations in familial or sporadic forms of the disease, according to the age at onset, and
  • to identify the genetic susceptibility factors in Parkinson’s disease with the study of affected sibpairs and with case/controls association studies.

For epilepsies, the aims are:

  • to evaluate the frequency, the nature and the phenotype associated with SCN1A, SCNab and GABR2 gene mutations in familial or sporadic forms of the affection associated with febrile seizures, and
  • to search for an intervention SCN1A, SCN1B and GABRG2 as susceptible genes in these forms of epilepsies.

Condition Phase
Parkinson's Disease Epilepsy Phase 1

Study Type: Observational
Study Design: Observational Model: Case Control
Observational Model: Natural History
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: The DNA and Cell Bank of IFR of Neurosciences: Clinical and Genetic Study of Parkinson's Disease and Epilepsies

Resource links provided by NLM:


Further study details as provided by Institut National de la Santé Et de la Recherche Médicale, France:

Estimated Enrollment: 1700
Study Start Date: May 2004
Estimated Study Completion Date: December 2006
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   1 Year to 90 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients presenting with Parkinson's disease, with a family history or not,
  • Minors presenting clinical signs of the disease,
  • Controls (without signs of the disease), matched by sex and age with the patients,
  • Relatives for the familial cases,
  • Patients presenting with an epilepsy episode (myoclonic epilepsy of the newborn, with febrile seizures, of the frontal lobe)

Exclusion Criteria:

  • Lack of signed informed consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00142363


Locations
France
Centre Hospitalier du Pays d'Aix
Aix-en-Provence, France, 13616
Hôpital Gabriel Montpied
Clermont-Ferrand, France, 63000
CHU de Grenoble
Grenoble, France, 38000
Hôpital Roger Salengro
Lille, France, 59000
Hôpital Neurologique Pierre Wertheimer
Lyon, France, 69003
Hôpital René et Guillaume Laennec
Nantes, France, 44000
Hôpital Pasteur
Nice, France, 06000
Hôpital Saint-Antoine
Paris, France, 75012
Hôpital Pitié-Salpêtrière
Paris, France, 75013
Pitié-Salpêtrière Hospital - Centre of Clinical Investigations
Paris, France, 75013
Hôpital Robert Debré
Paris, France, 75019
Hôpital Haut-Lévêque
Pessac, France, 33604
Hôpital Pontchaillou
Rennes, France, 35000
Hôpital Civil
Strasbourg, France, 67000
Hôpital Purpan
Toulouse, France, 31000
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Ministry of Health, France
Investigators
Principal Investigator: Alexis Brice, MD Assistance Publique - Hôpitaux de Paris, University Paris 6
  More Information

Additional Information:
Publications:
Ibáñez P, Bonnet AM, Débarges B, Lohmann E, Tison F, Pollak P, Agid Y, Dürr A, Brice A. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet. 2004 Sep 25-Oct 1;364(9440):1169-71.
Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet. 2005 Aug;77(2):330-2.
Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, Leutenegger AL, Guimaraes J, Bonnet AM, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol. 2005 Nov;58(5):784-7.
Lesage S, Leutenegger AL, Brice A. [LRRK2: a gene belonging to the ROCO family is implicated in the Parkinson's disease]. Med Sci (Paris). 2005 Dec;21(12):1015-7. French.
Ibáñez P, Lesage S, Lohmann E, Thobois S, De Michele G, Borg M, Agid Y, Dürr A, Brice A; French Parkinson's Disease Genetics Study Group. Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa. Brain. 2006 Mar;129(Pt 3):686-94. Epub 2006 Jan 9.
Lesage S, Dürr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, Pollak P, Brice A; French Parkinson's Disease Genetics Study Group. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med. 2006 Jan 26;354(4):422-3.

ClinicalTrials.gov Identifier: NCT00142363     History of Changes
Other Study ID Numbers: 4CH03G
First Submitted: September 1, 2005
First Posted: September 2, 2005
Last Update Posted: March 1, 2006
Last Verified: February 2006

Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
Parkinson's disease
Parkin
Epilepsy
Phenotype-genotype correlations
Ionic channels

Additional relevant MeSH terms:
Parkinson Disease
Epilepsy
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases


To Top